Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» GW Pharma
GW Pharma
Quiet times return for biopharma takeouts
Quiet times return for biopharma takeouts
EP Vantage
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Flag link:
Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90% premium sealed the deal — along with $17.6M in ‘retention’ incentives
Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90% premium sealed the deal — along with $17.6M in ‘retention’ incentives
Endpoints
Jazz Pharmaceuticals
Pharma CEOs
Justin Glover
GW Pharma
M&A
Flag link:
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharmaforum
pharma industry
R&D
pandemic
earnings
COVID-19
Biogen
GW Pharma
Jazz Pharmaceuticals
GSK
Merck KGaA
Flag link:
GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4
GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4
Motley Fool
GW Pharma
earnings
Flag link:
Jazz Pharma to acquire GW Pharma for $7.2 billion, adding CBD-based treatment for severe epilepsy
Jazz Pharma to acquire GW Pharma for $7.2 billion, adding CBD-based treatment for severe epilepsy
Stat
Jazz Pharma
GW Pharma
M&A
CBD
epilepsy
Epidiolex
Flag link:
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
BioSpace
GW Pharma
cannabindoids
multiple sclerosis
spasticity
nabiximols
Sativex
Flag link:
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Endpoints
Ovid Therapeutics
clinical trials
Takeda
Dravet syndrome
Lennox-Gastaut Syndrome
GW Pharma
Flag link:
GW Pharmaceuticals' Epidiolex Wins New FDA Approvals
GW Pharmaceuticals' Epidiolex Wins New FDA Approvals
Motley Fool
GW Pharma
Cannabidiol
Epidiolex
FDA
tuberous sclerosis complex
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
Flag link:
How GW Pharmaceuticals Hit a Home Run in Q1
How GW Pharmaceuticals Hit a Home Run in Q1
Motley Fool
GW Pharma
earnings
Epidiolex
Flag link:
GW Pharma tops list of UK R&D spenders
GW Pharma tops list of UK R&D spenders
Pharmaforum
GW Pharma
UK
R&D
Flag link:
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Motley Fool
Zogenix
epilepsy
Lennox-Gastaut Syndrome
clinical trials
Fintepla
GW Pharma
Epidiolex
Flag link:
Zogenix hands GW a win
Zogenix hands GW a win
EP Vantage
Lennox-Gastaut Syndrome
clinical trials
Fintepla
Zogenix
GW Pharma
Flag link:
GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations
GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations
Motley Fool
GW Pharma
earnings
Flag link:
Where Will GW Pharmaceuticals Be in 5 Years?
Where Will GW Pharmaceuticals Be in 5 Years?
Motley Fool
GW Pharma
cannabindoids
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
GW's Epidiolex topped sales predictions, but investors bailed. What gives?
GW's Epidiolex topped sales predictions, but investors bailed. What gives?
Fierce Pharma
GW Pharma
Epidiolex
Flag link:
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
Endpoints
GW Pharma
Europe
Epidyolex
Epidiolex
Flag link:
For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago
For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago
Xconomy
GW Pharma
Pharma CEOs
Justin Gover
Flag link:
GW confident epilepsy drug will get NHS funding despite NICE rejection
GW confident epilepsy drug will get NHS funding despite NICE rejection
Pharmaforum
GW Pharma
UK
NHS
NICE
Epidyolex
epilepsy
Flag link:
Pages
1
2
3
4
5
6
next ›
last »